Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(2):148–153. doi: 10.1038/bjc.1996.28

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

P Korkolopoulou 1, L Kaklamanis 1, F Pezzella 1, A L Harris 1, K C Gatter 1
PMCID: PMC2074307  PMID: 8546899

Abstract

Presentation of endogenous antigenic peptides to cytotoxic T lymphocytes is mediated by the major histocompatibility complex (MHC) class I molecules. For the stable assembly of MHC class I complex it is necessary that the antigenic peptide is transported by the MHC-encoded transporters TAP-1 and TAP-2 into a pre-Golgi region. T-cell-mediated host-vs-tumour response might therefore depend on the presence of these molecules on tumour cells. The presence of MHC class I antigens and TAP-1 was studied in a series of 93 resection specimens of non-small-cell lung carcinomas (NSCLCs) by immunohistochemical methods using antibodies against the assembled class I molecule, beta 2-microglobulin (beta 2-m), heavy-chain A locus, A2 allele and TAP-1 protein. Eighty-six patients were included in the survival analysis. Total loss of class I molecule was observed in 38% of the cases and was usually accompanied by loss of beta 2-m and of heavy chain A locus. Selective loss of A locus was seen in 8.3% and of A2 allele in 27% of the cases. TAP-1 loss was always combined with beta 2-m and/or heavy chain A locus loss. No correlation was found between the expressional status of any of the above molecules, including the selective A2 allelic loss and histological type, degree of differentiation, tumoral stage, nodal stage and survival. Our findings suggest that loss of antigen-presenting molecules (including both MHC class I alleles and TAP-1) is a frequent event in lung cancer. However, the immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth or survival of NSCLC.

Full text

PDF
148

Images in this article

150Figure 1
on p.150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arce-Gomez B., Jones E. A., Barnstable C. J., Solomon E., Bodmer W. F. The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens. 1978 Feb;11(2):96–112. doi: 10.1111/j.1399-0039.1978.tb01233.x. [DOI] [PubMed] [Google Scholar]
  2. Barnstable C. J., Bodmer W. F., Brown G., Galfre G., Milstein C., Williams A. F., Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 1978 May;14(1):9–20. doi: 10.1016/0092-8674(78)90296-9. [DOI] [PubMed] [Google Scholar]
  3. Bodmer W. F. The HLA system: structure and function. J Clin Pathol. 1987 Sep;40(9):948–958. doi: 10.1136/jcp.40.9.948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brodsky F. M., Bodmer W. F., Parham P. Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol. 1979 Jul;9(7):536–545. doi: 10.1002/eji.1830090709. [DOI] [PubMed] [Google Scholar]
  5. Concha A., Cabrera T., Ruiz-Cabello F., Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl. 1991;6:146–154. doi: 10.1002/ijc.2910470726. [DOI] [PubMed] [Google Scholar]
  6. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  7. Cromme F. V., Airey J., Heemels M. T., Ploegh H. L., Keating P. J., Stern P. L., Meijer C. J., Walboomers J. M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med. 1994 Jan 1;179(1):335–340. doi: 10.1084/jem.179.1.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Daar A. S., Fuggle S. V., Fabre J. W., Ting A., Morris P. J. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation. 1984 Sep;38(3):287–292. doi: 10.1097/00007890-198409000-00018. [DOI] [PubMed] [Google Scholar]
  9. Dausset J. The major histocompatibility complex in man. Science. 1981 Sep 25;213(4515):1469–1474. doi: 10.1126/science.6792704. [DOI] [PubMed] [Google Scholar]
  10. Doyle A., Martin W. J., Funa K., Gazdar A., Carney D., Martin S. E., Linnoila I., Cuttitta F., Mulshine J., Bunn P. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985 May 1;161(5):1135–1151. doi: 10.1084/jem.161.5.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dämmrich J., Müller-Hermelink H. K., Mattner A., Buchwald J., Ziffer S. Histocompatibility antigen expression in pulmonary carcinomas as indication of differentiation and of special subtypes. Cancer. 1990 May 1;65(9):1942–1954. doi: 10.1002/1097-0142(19900501)65:9<1942::aid-cncr2820650912>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Festenstein H., Garrido F. MHC antigens and malignancy. Nature. 1986 Aug 7;322(6079):502–503. doi: 10.1038/322502a0. [DOI] [PubMed] [Google Scholar]
  13. Funa K., Gazdar A. F., Minna J. D., Linnoila R. I. Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors. Lab Invest. 1986 Aug;55(2):186–193. [PubMed] [Google Scholar]
  14. Goepel J. R., Rees R. C., Rogers K., Stoddard C. J., Thomas W. E., Shepherd L. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer. 1991 Nov;64(5):880–883. doi: 10.1038/bjc.1991.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hakem R., Le Bouteiller P., Barad M., Trujillo M., Mercier P., Wietzerbin J., Lemonnier F. A. IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes. J Immunol. 1989 Jan 1;142(1):297–305. [PubMed] [Google Scholar]
  16. Hui K., Grosveld F., Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 1984 Oct 25;311(5988):750–752. doi: 10.1038/311750a0. [DOI] [PubMed] [Google Scholar]
  17. Kaklamanis L., Gatter K. C., Hill A. B., Mortensen N., Harris A. L., Krausa P., McMichael A., Bodmer J. G., Bodmer W. F. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer. 1992 May 28;51(3):379–385. doi: 10.1002/ijc.2910510308. [DOI] [PubMed] [Google Scholar]
  18. Kaklamanis L., Townsend A., Doussis-Anagnostopoulou I. A., Mortensen N., Harris A. L., Gatter K. C. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994 Sep;145(3):505–509. [PMC free article] [PubMed] [Google Scholar]
  19. Kelly A., Powis S. H., Kerr L. A., Mockridge I., Elliott T., Bastin J., Uchanska-Ziegler B., Ziegler A., Trowsdale J., Townsend A. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature. 1992 Feb 13;355(6361):641–644. doi: 10.1038/355641a0. [DOI] [PubMed] [Google Scholar]
  20. Kleijmeer M. J., Kelly A., Geuze H. J., Slot J. W., Townsend A., Trowsdale J. Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature. 1992 May 28;357(6376):342–344. doi: 10.1038/357342a0. [DOI] [PubMed] [Google Scholar]
  21. Kärre K., Ljunggren H. G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986 Feb 20;319(6055):675–678. doi: 10.1038/319675a0. [DOI] [PubMed] [Google Scholar]
  22. López-Nevot M. A., Esteban F., Ferrón A., Gutiérrez J., Oliva M. R., Romero C., Huelin C., Ruiz-Cabello F., Garrido F. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer. 1989 Feb;59(2):221–226. doi: 10.1038/bjc.1989.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McMichael A. J., Parham P., Rust N., Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol. 1980 Sep;1(2):121–129. doi: 10.1016/0198-8859(80)90099-3. [DOI] [PubMed] [Google Scholar]
  24. Momburg F., Ziegler A., Harpprecht J., Möller P., Moldenhauer G., Hämmerling G. J. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol. 1989 Jan 1;142(1):352–358. [PubMed] [Google Scholar]
  25. Möller P., Momburg F., Koretz K., Moldenhauer G., Herfarth C., Otto H. F., Hämmerling G. J., Schlag P. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991 Jan 15;51(2):729–736. [PubMed] [Google Scholar]
  26. Orgad S., Yang S. Y., Gazit E., Relias V., Zaizov R., Lyson S., Yunis E. J. Expression of extra class I major histocompatibility antigens on T-cell acute lymphoblastic leukemia (ALL) lymphoblasts. Hum Immunol. 1985 Mar;12(3):133–141. doi: 10.1016/0198-8859(85)90331-3. [DOI] [PubMed] [Google Scholar]
  27. Ortmann B., Androlewicz M. J., Cresswell P. MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature. 1994 Apr 28;368(6474):864–867. doi: 10.1038/368864a0. [DOI] [PubMed] [Google Scholar]
  28. Parham P., Barnstable C. J., Bodmer W. F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol. 1979 Jul;123(1):342–349. [PubMed] [Google Scholar]
  29. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ploegh H. L., Orr H. T., Strominger J. L. Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell. 1981 May;24(2):287–299. doi: 10.1016/0092-8674(81)90318-4. [DOI] [PubMed] [Google Scholar]
  31. Redondo M., Concha A., Oldiviela R., Cueto A., Gonzalez A., Garrido F., Ruiz-Cabello F. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 1991 Sep 15;51(18):4948–4954. [PubMed] [Google Scholar]
  32. Redondo M., Ruiz-Cabello F., Concha A., Cabrera T., Pérez-Ayala M., Oliva M. R., Garrido F. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res. 1991 May 1;51(9):2463–2468. [PubMed] [Google Scholar]
  33. Rees R. C., Buckle A. M., Gelsthorpe K., James V., Potter C. W., Rogers K., Jacob G. Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br J Cancer. 1988 Apr;57(4):374–377. doi: 10.1038/bjc.1988.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schmidt H., Gekeler V., Haas H., Engler-Blum G., Steiert I., Probst H., Müller C. A. Differential regulation of HLA class I genes by interferon. Immunogenetics. 1990;31(4):245–252. doi: 10.1007/BF00204896. [DOI] [PubMed] [Google Scholar]
  35. Sobin L. H. The World Health Organization's Histological Classification of Lung Tumors: a comparison of the first and second editions. Cancer Detect Prev. 1982;5(4):391–406. [PubMed] [Google Scholar]
  36. Spies T., Cerundolo V., Colonna M., Cresswell P., Townsend A., DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature. 1992 Feb 13;355(6361):644–646. doi: 10.1038/355644a0. [DOI] [PubMed] [Google Scholar]
  37. Stam N. J., Vroom T. M., Peters P. J., Pastoors E. B., Ploegh H. L. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol. 1990;2(2):113–125. doi: 10.1093/intimm/2.2.113. [DOI] [PubMed] [Google Scholar]
  38. Stein B., Momburg F., Schwarz V., Schlag P., Moldenhauer G., Möller P. Reduction or loss of HLA-A,B,C antigens in colorectal carcinoma appears not to influence survival. Br J Cancer. 1988 Apr;57(4):364–368. doi: 10.1038/bjc.1988.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tanaka K., Isselbacher K. J., Khoury G., Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 1985 Apr 5;228(4695):26–30. doi: 10.1126/science.3975631. [DOI] [PubMed] [Google Scholar]
  40. Townsend A., Elliott T., Cerundolo V., Foster L., Barber B., Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell. 1990 Jul 27;62(2):285–295. doi: 10.1016/0092-8674(90)90366-m. [DOI] [PubMed] [Google Scholar]
  41. Trowsdale J., Hanson I., Mockridge I., Beck S., Townsend A., Kelly A. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature. 1990 Dec 20;348(6303):741–744. doi: 10.1038/348741a0. [DOI] [PubMed] [Google Scholar]
  42. Wallich R., Bulbuc N., Hämmerling G. J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985 May 23;315(6017):301–305. doi: 10.1038/315301a0. [DOI] [PubMed] [Google Scholar]
  43. Wintzer H. O., Benzing M., von Kleist S. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer. 1990 Aug;62(2):289–295. doi: 10.1038/bjc.1990.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zinkernagel R. M., Doherty P. C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol. 1979;27:51–177. doi: 10.1016/s0065-2776(08)60262-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES